Hormone pill may cut heart risk in perimenopause, small study suggests
NCT ID NCT07609043
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed Phase 3 trial tested whether taking 50 mg of prasterone (DHEA) daily for 2 months could improve cardiometabolic indicators in perimenopausal women. The study enrolled 25 women and measured changes in insulin resistance and lipid levels. The goal is to find a way to prevent metabolic and cardiovascular complications that often arise during the transition to menopause.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
prasterone (DHEA)
What this could lead to
If successful, this could point toward a hormone therapy to reduce cardiometabolic risk during perimenopause.
What could go wrong
This is a very small, completed Phase 3 trial with only 25 participants, so results may not apply broadly. DHEA can have hormonal side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARDIO METABOLIC RISK are added.
By submitting, you agree to our Terms of use
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Universidad de Guanajuato
Mexico City, Guanajuato, 36000, Mexico